133 related articles for article (PubMed ID: 20701608)
1. A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients.
Ishiguro T; Kawai S; Habu K; Sugimoto M; Shiraiwa H; Iijima S; Ozaki S; Matsumoto T; Yamada-Okabe H
Cancer Sci; 2010 Oct; 101(10):2227-33. PubMed ID: 20701608
[TBL] [Abstract][Full Text] [Related]
2. Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors.
Harada T; Ozaki S; Oda A; Tsuji D; Ikegame A; Iwasa M; Udaka K; Fujii S; Nakamura S; Miki H; Kagawa K; Kuroda Y; Kawai S; Itoh K; Yamada-Okabe H; Matsumoto T; Abe M
PLoS One; 2013; 8(12):e83905. PubMed ID: 24386306
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models.
Kawai S; Yoshimura Y; Iida S; Kinoshita Y; Koishihara Y; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
Oncol Rep; 2006 Feb; 15(2):361-7. PubMed ID: 16391855
[TBL] [Abstract][Full Text] [Related]
4. Construction of a conventional non-radioisotope method to quantify HM1.24 antigens: correlation of HM1.24 levels and ADCC activity of the humanized antibody against HM1.24.
Kawai S; Koishihara Y; Iida S; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
Leuk Res; 2006 Aug; 30(8):949-56. PubMed ID: 16473407
[TBL] [Abstract][Full Text] [Related]
5. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.
Yamane-Ohnuki N; Kinoshita S; Inoue-Urakubo M; Kusunoki M; Iida S; Nakano R; Wakitani M; Niwa R; Sakurada M; Uchida K; Shitara K; Satoh M
Biotechnol Bioeng; 2004 Sep; 87(5):614-22. PubMed ID: 15352059
[TBL] [Abstract][Full Text] [Related]
6. Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models.
Kawai S; Azuma Y; Fujii E; Furugaki K; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
Cancer Sci; 2008 Dec; 99(12):2461-6. PubMed ID: 19032371
[TBL] [Abstract][Full Text] [Related]
7. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells.
Ozaki S; Kosaka M; Wakahara Y; Ozaki Y; Tsuchiya M; Koishihara Y; Goto T; Matsumoto T
Blood; 1999 Jun; 93(11):3922-30. PubMed ID: 10339501
[TBL] [Abstract][Full Text] [Related]
8. Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC.
Imai-Nishiya H; Mori K; Inoue M; Wakitani M; Iida S; Shitara K; Satoh M
BMC Biotechnol; 2007 Nov; 7():84. PubMed ID: 18047682
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy for HM1.24 (CD317) on multiple myeloma cells.
Harada T; Ozaki S
Biomed Res Int; 2014; 2014():965384. PubMed ID: 25143955
[TBL] [Abstract][Full Text] [Related]
10. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody.
Wang W; Nishioka Y; Ozaki S; Jalili A; Abe S; Kakiuchi S; Kishuku M; Minakuchi K; Matsumoto T; Sone S
Cancer Immunol Immunother; 2009 Jun; 58(6):967-76. PubMed ID: 18979097
[TBL] [Abstract][Full Text] [Related]
11. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
12. Producing defucosylated antibodies with enhanced in vitro antibody-dependent cellular cytotoxicity via
Zong H; Han L; Ding K; Wang J; Sun T; Zhang X; Cagliero C; Jiang H; Xie Y; Xu J; Zhang B; Zhu J
Eng Life Sci; 2017 Jul; 17(7):801-808. PubMed ID: 32624826
[TBL] [Abstract][Full Text] [Related]
13. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
15. Antigen-dependent internalization is related to rapid elimination from plasma of humanized anti-HM1.24 monoclonal antibody.
Amano J; Masuyama N; Hirota Y; Tanaka Y; Igawa Y; Shiokawa R; Okutani T; Miyayama T; Nanami M; Ishigai M
Drug Metab Dispos; 2010 Dec; 38(12):2339-46. PubMed ID: 20823293
[TBL] [Abstract][Full Text] [Related]
16. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity.
Shinkawa T; Nakamura K; Yamane N; Shoji-Hosaka E; Kanda Y; Sakurada M; Uchida K; Anazawa H; Satoh M; Yamasaki M; Hanai N; Shitara K
J Biol Chem; 2003 Jan; 278(5):3466-73. PubMed ID: 12427744
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24.
Ozaki S; Kosaka M; Wakatsuki S; Abe M; Koishihara Y; Matsumoto T
Blood; 1997 Oct; 90(8):3179-86. PubMed ID: 9376601
[TBL] [Abstract][Full Text] [Related]
18. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA.
Mori K; Kuni-Kamochi R; Yamane-Ohnuki N; Wakitani M; Yamano K; Imai H; Kanda Y; Niwa R; Iida S; Uchida K; Shitara K; Satoh M
Biotechnol Bioeng; 2004 Dec; 88(7):901-8. PubMed ID: 15515168
[TBL] [Abstract][Full Text] [Related]
19. Antitumor Activities in Mouse Xenograft Models of Canine Mammary Gland Tumor by Defucosylated Mouse-Dog Chimeric Anti-Epidermal Growth Factor Receptor Antibody (E134Bf).
Li G; Suzuki H; Takei J; Asano T; Sano M; Tanaka T; Harada H; Mizuno T; Ohishi T; Kawada M; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2022 Apr; 41(2):53-58. PubMed ID: 35471048
[TBL] [Abstract][Full Text] [Related]
20. The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity.
Ono K; Ohtomo T; Yoshida K; Yoshimura Y; Kawai S; Koishihara Y; Ozaki S; Kosaka M; Tsuchiya M
Mol Immunol; 1999 Apr; 36(6):387-95. PubMed ID: 10444002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
